Form 4: ARTELO Director Blayney Receives Stock Option Grant

ARTELO BIOSCIENCES Director Douglas Blayney was granted 292 stock options with an exercise price of $1.71, vesting on January 30, 2027, or earlier.

Summary

• Douglas Blayney, a Director of ARTELO BIOSCIENCES, INC. (ARTL), was granted 292 stock options.
• The stock options have an exercise price of $1.71 per share.
• The vesting commencement date for these options is January 30, 2026.
• The options are scheduled to expire on January 30, 2036.
• One hundred percent (100%) of the shares subject to the option will vest on the earlier of (i) the one-year anniversary of the Vesting Commencement Date (January 30, 2027), or (ii) the day prior to the date of the annual meeting of the Issuer's stockholders next following the Vesting Commencement Date.
• Following this transaction, Douglas Blayney beneficially owns 292 derivative securities directly.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, as it represents a standard compensation practice that aligns director interests with shareholder value, without indicating any significant operational or financial changes.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, incentivizing long-term performance.
• The options have a 10-year expiration period, providing a long-term incentive for the director.

Future Outlook

The vesting schedule indicates an expectation for Douglas Blayney to continue as a Service Provider to ARTELO BIOSCIENCES, INC. for at least one year from the vesting commencement date, or until the next annual meeting of stockholders, to fully realize the benefit of the option grant.

Industry Context

StockSavvy.ai notes that granting stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive compensation packages designed to align leadership incentives with long-term shareholder value creation.

Stakeholder Impact

• Shareholders: Potential for increased alignment between director and shareholder interests due to equity-based compensation.

Next Steps

• Continued service of Douglas Blayney as a Director.
• Vesting of the 292 stock options on the specified date (earlier of January 30, 2027, or the day prior to the next annual meeting).
• Potential exercise of vested options by Douglas Blayney before the expiration date of January 30, 2036.

Key Dates

Recommendation

This Form 4 reports a routine grant of stock options to a director, which is a standard compensation practice. It does not provide new fundamental information to alter an investment thesis, thus a 'hold' recommendation is appropriate based solely on this filing.

Keywords

ARTL, Artelo Biosciences, stock options, insider transaction, Form 4, director compensation, equity grant, beneficial ownership